Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Israfil Baluwala, Emmanuel J. Favaloro & Leonardo Pasalic. (2017) Therapeutic monitoring of unfractionated heparin – trials and tribulations. Expert Review of Hematology 10:7, pages 595-605.
Read now
Read now
Articles from other publishers (11)
Tomoyo Saito, Mineji Hayakawa, Osamu Kumano, Yoshinori Honma, Mone Murashita, Jun Kato, Syouki Fukui, Masaki Takahashi, Yuki Takahashi, Takumi Tsuchida, Asumi Mizugaki, Shuhei Takauji, Mariko Hayamizu, Tomonao Yoshida, Kenichi Katabami, Takeshi Wada & Kunihiko Maekawa. (2023) Variation in coagulation factor activity levels cause discrepancies between activated partial thromboplastin time and anti-Xa activity for heparin monitoring: a retrospective observational study. Journal of Intensive Care 11:1.
Crossref
Crossref
Richard J. Haftmann, Erika May Pineda, Brent A. Hall, Machelle D. Wilson & Stephanie N. Mateev. (2023) Comparison of Time Within Therapeutic Range Using Anti-Factor Xa Versus Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin in Children. The Journal of Pediatric Pharmacology and Therapeutics 28:3, pages 228-234.
Crossref
Crossref
Mark T. Friedman, Kamille A. West, Peyman Bizargity, Kyle Annen, H. Deniz Gur & Timothy HilbertMark T. Friedman, Kamille A. West, Peyman Bizargity, Kyle Annen, H. Deniz Gur & Timothy Hilbert. 2023. Immunohematology, Transfusion Medicine, Hemostasis, and Cellular Therapy. Immunohematology, Transfusion Medicine, Hemostasis, and Cellular Therapy
545
551
.
Wedali E Jimaja, Jerome Stirnemann, Pierre Fontana & Katherine S Blondon. (2022) Improving safety of unfractionated heparin: a retrospective, quasi-experimental, observational study of the impact of a pocket card and a computerised prescription aid tool in the University Hospitals of Geneva. BMJ Open 12:3, pages e056912.
Crossref
Crossref
Rebecca Swayngim, Candice Preslaski, Clay Cothren Burlew & Jacob Beyer. (2021) Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: A systematic review and meta-analysis. Thrombosis Research 208, pages 18-25.
Crossref
Crossref
Motalib Smahi, Neila De Pooter, Martine J. Hollestelle & Pierre Toulon. (2020) Monitoring unfractionated heparin therapy: Lack of standardization of anti‐Xa activity reagents. Journal of Thrombosis and Haemostasis 18:10, pages 2613-2621.
Crossref
Crossref
Tanya Williams-NorwoodMegan CaswellBarbara MilnerJoseph C. VesceraKelly PrymiczAmy G. CiszakCarol IngleChristopher LaceyEvi X. Stavrou. (2020) Design and Implementation of an Anti–Factor Xa Heparin Monitoring Protocol. AACN Advanced Critical Care 31:2, pages 129-137.
Crossref
Crossref
Nabiha H. Saifee, Thomas V. Brogan, David M. McMullan, Larissa Yalon, Dana C. Matthews, Christopher R. Burke & Wayne L. Chandler. (2020) Monitoring Hemostasis During Extracorporeal Life Support. ASAIO Journal 66:2, pages 230-237.
Crossref
Crossref
Surbhi Saini, Ashley N. Folta, Katherine L. Harsh, Joseph R. Stanek, Amy L. Dunn, Sarah H. O'Brien & Riten Kumar. (2019) Anti-Factor Xa–Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort. The Journal of Pediatrics 209, pages 212-219.e1.
Crossref
Crossref
Natalie Henderson, Janice E. Sullivan, John Myers, Terri Wells, Aaron Calhoun, John Berkenbosch & Deanna Todd Tzanetos. (2018) Use of Thromboelastography to Predict Thrombotic Complications in Pediatric and Neonatal Extracorporeal Membranous Oxygenation. The Journal of ExtraCorporeal Technology 50:3, pages 149-154.
Crossref
Crossref
M. Trucco, C.U. Lehmann, N. Mollenkopf, M.B. Streiff & C.M. Takemoto. (2015) Retrospective cohort study comparing activated partial thromboplastin time versus anti‐factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics. Journal of Thrombosis and Haemostasis 13:5, pages 788-794.
Crossref
Crossref